These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 37329712

  • 1. Discovery of N-(2-chloro-5-(3-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide (FD274) as a highly potent PI3K/mTOR dual inhibitor for the treatment of acute myeloid leukemia.
    Yang C, Chen Y, Wu T, Gao Y, Liu X, Yang Y, Ling Y, Jia Y, Deng M, Wang J, Zhou Y.
    Eur J Med Chem; 2023 Oct 05; 258():115543. PubMed ID: 37329712
    [Abstract] [Full Text] [Related]

  • 2. Insilco and Invitro approaches identify novel dual PI3K/AKT pathway inhibitors to control acute myeloid leukemia cell proliferations.
    Abohassan M, Alshahrani M, Alshahrani MY, Rajagopalan P.
    Med Oncol; 2022 Oct 08; 39(12):249. PubMed ID: 36209300
    [Abstract] [Full Text] [Related]

  • 3. Anti-leukemia effects of omipalisib in acute myeloid leukemia: inhibition of PI3K/AKT/mTOR signaling and suppression of mitochondrial biogenesis.
    Tseng CY, Fu YH, Ou DL, Lu JW, Hou HA, Lin LI.
    Cancer Gene Ther; 2023 Dec 08; 30(12):1691-1701. PubMed ID: 37821641
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The PI3K/mTOR dual inhibitor BEZ235 suppresses proliferation and migration and reverses multidrug resistance in acute myeloid leukemia.
    Deng L, Jiang L, Lin XH, Tseng KF, Liu Y, Zhang X, Dong RH, Lu ZG, Wang XJ.
    Acta Pharmacol Sin; 2017 Mar 08; 38(3):382-391. PubMed ID: 28042875
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Discovery of a series of N-(5-(quinolin-6-yl)pyridin-3-yl)benzenesulfonamides as PI3K/mTOR dual inhibitors.
    Zhang J, Lv X, Ma X, Hu Y.
    Eur J Med Chem; 2017 Feb 15; 127():509-520. PubMed ID: 28109945
    [Abstract] [Full Text] [Related]

  • 8. Design, synthesis and pharmacological evaluation of 2-arylurea-1,3,5-triazine derivative (XIN-9): A novel potent dual PI3K/mTOR inhibitor for cancer therapy.
    Sun X, Zhang B, Luo L, Yang Y, He B, Zhang Q, Wang L, Xu S, Zheng P, Zhu W.
    Bioorg Chem; 2022 Dec 15; 129():106157. PubMed ID: 36209563
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A pyridinesulfonamide derivative FD268 suppresses cell proliferation and induces apoptosis via inhibiting PI3K pathway in acute myeloid leukemia.
    Chen Y, Wu T, Yang C, Lu M, Chen Z, Deng M, Jia Y, Yang Y, Liu X, Wang H, Ling Y, Lu L, Zhou Y.
    PLoS One; 2022 Dec 15; 17(11):e0277893. PubMed ID: 36413544
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. PI3K/mTOR dual-inhibition with VS-5584 enhances anti-leukemic efficacy of ponatinib in blasts and Ph-negative LSCs of chronic myeloid leukemia.
    Kayabasi C, Yelken BO, Asik A, Okcanoglu TB, Sogutlu F, Gasimli R, Susluer SY, Saydam G, Avci CB, Gunduz C.
    Eur J Pharmacol; 2021 Nov 05; 910():174446. PubMed ID: 34461124
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia.
    Tabe Y, Tafuri A, Sekihara K, Yang H, Konopleva M.
    Expert Opin Ther Targets; 2017 Jul 05; 21(7):705-714. PubMed ID: 28537457
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML.
    Herschbein L, Liesveld JL.
    Blood Rev; 2018 May 05; 32(3):235-248. PubMed ID: 29276026
    [Abstract] [Full Text] [Related]

  • 20. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.
    Martelli AM, Evangelisti C, Chiarini F, McCubrey JA.
    Oncotarget; 2010 Jun 05; 1(2):89-103. PubMed ID: 20671809
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.